Literature DB >> 14764889

Dual-modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation.

Gerald Antoch1, Hilmar Kuehl, Jörg Kanja, Thomas C Lauenstein, Hubert Schneemann, Elke Hauth, Walter Jentzen, Thomas Beyer, Susanne C Goehde, Jörg F Debatin.   

Abstract

The authors qualitatively and quantitatively assessed a solution containing 0.2% locust bean gum (LBG) and 2.5% mannitol (mannitol-LBG) dissolved in water to provide a negative oral contrast material in dual-modality positron emission tomography (PET)/computed tomography (CT) scanning. PET/CT was performed in 60 patients with cancer after oral administration of barium, water, or mannitol-LBG. Qualitative and quantitative analyses were conducted to determine bowel distention and a potential influence of the contrast agents on the PET data. Intestinal distention with mannitol-LBG proved superior to that with water or barium. Findings at both quantitative and qualitative analysis revealed apparently increased tracer uptake in the small bowel with barium in comparison to that with mannitol-LBG or water. Mannitol-LBG may, therefore, be used as a negative oral contrast agent at PET/CT scanning because it provides excellent bowel distention while avoiding contrast material-induced PET artifacts. Copyright RSNA, 2004

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14764889     DOI: 10.1148/radiol.2303021287

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  31 in total

1.  Calcified Lymph Nodes Causing Clinically Relevant Attenuation Correction Artifacts on PET/CT Imaging.

Authors:  Amar Mehta; Ajeet Mehta; Charles Laymon; Todd M Blodgett
Journal:  J Radiol Case Rep       Date:  2010-02-01

2.  Neutral vs positive oral contrast in diagnosing acute appendicitis with contrast-enhanced CT: sensitivity, specificity, reader confidence and interpretation time.

Authors:  D M Naeger; S D Chang; P Kolli; V Shah; W Huang; R F Thoeni
Journal:  Br J Radiol       Date:  2010-10-19       Impact factor: 3.039

3.  Assessment of errors caused by X-ray scatter and use of contrast medium when using CT-based attenuation correction in PET.

Authors:  Mohammad Reza Ay; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-19       Impact factor: 9.236

4.  Oral contrast medium in PET/CT: should you or shouldn't you?

Authors:  Ashley M Groves; Irfan Kayani; John C Dickson; Caroline Townsend; Ian Croasdale; Rizwan Syed; Nagesh Nagabushan; Sharon F Hain; Peter J Ell; Jamshed B Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2005-06-04       Impact factor: 9.236

5.  Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.

Authors:  L S Freudenberg; G Antoch; A Frilling; W Jentzen; S J Rosenbaum; H Kühl; A Bockisch; R Görges
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-01-12       Impact factor: 9.236

6.  The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials.

Authors:  Ronald Boellaard; Wim J G Oyen; Corneline J Hoekstra; Otto S Hoekstra; Eric P Visser; Antoon T Willemsen; Bertjan Arends; Fred J Verzijlbergen; Josee Zijlstra; Anne M Paans; Emile F I Comans; Jan Pruim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-08-15       Impact factor: 9.236

7.  Correction of oral contrast artifacts in CT-based attenuation correction of PET images using an automated segmentation algorithm.

Authors:  Alireza Ahmadian; Mohammad R Ay; Javad H Bidgoli; Saeed Sarkar; Habib Zaidi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-04-17       Impact factor: 9.236

8.  Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients.

Authors:  C Riegger; J Herrmann; J Nagarajah; J Hecktor; S Kuemmel; F Otterbach; S Hahn; A Bockisch; T Lauenstein; G Antoch; T A Heusner
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-03-06       Impact factor: 9.236

9.  TNM staging with FDG-PET/CT in patients with primary head and neck cancer.

Authors:  Patrick Veit-Haibach; Christopher Luczak; Isabel Wanke; Markus Fischer; Thomas Egelhof; Thomas Beyer; Gerlinde Dahmen; Andreas Bockisch; Sandra Rosenbaum; Gerald Antoch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-08-24       Impact factor: 9.236

10.  Oral contrast agents for small bowel distension in MRI: influence of the osmolarity for small bowel distention.

Authors:  Waleed Ajaj; Mathias Goyen; Hubert Schneemann; Christiane Kuehle; Michael Nuefer; Stefan G Ruehm; Susanne C Goehde; Thomas C Lauenstein
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.